|Bid||122.26 x 800|
|Ask||122.50 x 3000|
|Day's Range||122.25 - 127.31|
|52 Week Range||70.50 - 176.50|
|Beta (3Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||204.35|
During the Lightning Round of Mad Money Thursday night, Jim Cramer had this to say about Sarepta Therapeutics, Inc. In the daily bar chart of SRPT, below, we can see that prices have been stuck in a sideways to lower trading range since June of last year. SRPT tested and broke the rising 200-day moving average line in December and January and again this month.
Sarepta and Amarin: How These Biotech Stocks Stack Up(Continued from Prior Part)Growth catalysts In its fourth-quarter earnings conference call, Sarepta Therapeutics (SRPT) highlighted its submission of an NDA (new drug application) in the fourth
Sarepta and Amarin: How These Biotech Stocks Stack Up(Continued from Prior Part)Growth trends In its fourth-quarter earnings conference call, Sarepta Therapeutics (SRPT) reported Exondys sales of around $301 million, a YoY rise of around 98%. In
Sarepta and Amarin: How These Biotech Stocks Stack Up(Continued from Prior Part)Revenue guidance In its fourth-quarter earnings conference call, Sarepta Therapeutics (SRPT) guided for fiscal 2019 revenues in the range of $365 million to $375 million,
Sarepta and Amarin: How These Biotech Stocks Stack UpStock price movementsOn March 11, Sarepta Therapeutics (SRPT) closed at $134.39, 2.74% higher than its previous closing price, 90.62% higher than its 52-week low of $70.50, and 23.86% below its
Sarepta Therapeutics Inc NASDAQ/NGS:SRPTView full report here! Summary * Bearish sentiment is moderate Bearish sentimentShort interest | NeutralShort interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold SRPT had net inflows of $1.61 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Sarepta Therapeutics (NASDAQ:SRPT) stock is taking a hit on Wednesday as the company made an announcement on Tuesday afternoon that sent shares tumbling.The Cambridge, Mass.-based medical research and drug development business, which focuses on precision genetic medicine for rare diseases, unveiled an underwritten public offering on Tuesday after the bell. The company will be offering more than 2.6 million shares of its common stock at a price of $144 per share to the public.Plus, Sarepta Therapeutics has also granted underwriters a 30-day option that would allow them to purchase roughly 390,625 shares of SRPT common stock on the same terms and conditions as the initial shares that were sold to the underwriters. The company predicts that the gross proceeds from the offering will be roughly $375 million before deducting the underwriter discounts and commissions, as well as other offering expenses.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe business added that it projects that the offering will be closed on or about March 7, 2019, according to customary closing conditions. Sarepta is reportedly intent on using the net proceeds from the offering for the main purpose of continuing and beginning more clinical trials.The proceeds will also be used in the commercialization, manufacturing, business development activities and any potential licensing or acquisition of complementary products for the trials.SRPT stock is down roughly 10.2% on Wednesday following the news. Shares had been falling about 2% after hours Tuesday off the heels of the announcement. More From InvestorPlace * 7 Top-Rated Stocks to Buy for March * 7 Chinese Stocks to Buy for the 2019 Rebound * 9 Trade War Stocks to Sell on U.S.-China Deal News Compare Brokers The post Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today appeared first on InvestorPlace.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 2,604,167 shares of its common stock at a price to the public of $144.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 390,625 shares of its common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $375.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $350,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase up to an additional $52,500,000 in shares of its common stock offered in the public offering. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are acting as the underwriters of the proposed offering.
The biotech industry has been on a tear in 2019, up 25% through the first two months of the year. That's great. But niche gene therapy stocks are performing even better.Source: Shutterstock The rally has been fueled by a strong combination of merger announcements, positive news from the FDA and the continued development of breakthrough therapies. Headlines have been popping up nonstop over the last week, and today I'd like to recap some of the highlights. Spark Therapeutics (NASDAQ:ONCE), a small-cap biotech that focuses on gene therapies, was purchased by pharmaceutical giant Roche (OTCMKTS:RHHBY). On a per-share basis, the $4.8 billion purchase price equated to $114.50 -- a huge 122% premium over ONCE's previous close. Spark investors are now looking at 190% gains in 2019 alone.The same day, CRISPR Therapeutics (NASDAQ:CRSP) announced that human trials had begun for its CTX001 gene therapy drug. A patient suffering from beta-thalassemia had been dosed. And in just a few months, the same drug is expected to be tested on patients with sickle cell disease.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCTX001, which is based on the CRISPR/Cas9 gene editing technique, is currently undergoing Phase I/II trials. Typically, the first dose in such a trial would not be a headline. But this was the first time that CRISPR technology had ever been used on a human. The news sent CRSP up more than 20%. * 7 Top-Rated Stocks to Buy for March A few days later, gene therapy stock Sarepta Therapeutics (NASDAQ:SRPT) released impressive results for its muscular dystrophy drug. And in the same press release it announced the $165 million purchase of privately-held gene therapy company Myonexus. The stock rallied on the news and is now up 34% so far this year. But even with the acquisition news, SRPT has long been rumored as a takeover target for larger pharmaceutical companies.Finally, micro-cap gene therapy stock MeiraGTx Holdings (NASDAQ:MGTX) announced an $80 million private placement. This is important because its lead investor is the private arm of Johnson & Johnson (NYSE:JNJ). MeiraGTx is already up a whopping 67% in 2019. Get in Position for Life-Changing Profits from Gene Therapy StocksThere is absolutely no question that there is money to be made in the gene therapy stocks over the long term. However, because the sector is still in its infancy, we have to expect increased volatility. What we're seeing now is a very strong upswing.Gene therapy is on track to save countless lives. It's also on track to make you life-changing profits as long as you can weather the ups and downs that are simply the nature of early-stage mega-trends.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever Compare Brokers The post Why NOW Is the Time to Buy Gene Therapy Stocks appeared first on InvestorPlace.
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seventeen individuals hired by Sarepta in February 2019. The employees received, in the aggregate, options to purchase 21,260 shares of Sarepta's common stock, and in the aggregate, 10,600 restricted stock units (“RSUs”). The options have an exercise price of $144.24 per share, which is equal to the closing price of Sarepta's common stock on February 28, 2019 (the “Grant Date”).
Sarepta Therapeutics Inc (NASDAQ: SRPT ) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. The Analysts Janney analyst Yun Zhong reiterated ...
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 20 individuals chosen by an independent committee of Duchenne community members based on an applicant’s community involvement and personal essay. The Route 79 program is designed to help students with Duchenne pursue their post-secondary educational goals.
A third gene therapy spinoff from Nationwide Children's Hospital has been acquired, this time for $165 million.
Inc. has exercised an option to buy startup Myonexus Therapeutics, continuing a string of acquisitions of gene-therapy companies. Sarepta is paying $165 million for Myonexus, which is developing gene therapies for limb girdle muscular dystrophies, a group of diseases causing weakness and wasting of muscles in the arms and legs. On Monday, Roche Holding AG said it would acquire Spark Therapeutics Inc. for $4.8 billion.
Sarepta Therapeutics stock jumped closer to a breakout Wednesday after its gene therapy showed promise in a form of limb-girdle muscle dystrophy. The disease is caused by lacking a protein.